Although the schizophrenia drug market is crowded, few, if any, effective therapies are available in the United States and Europe to treat the negative symptoms of schizophrenia (e.g., apathy, social withdrawal, affective flattening). Of note, AbbVie’s Vraylar / Gedeon Richter / Recordati’s Reagila has shown some efficacy for the treatment of predominant negative symptoms in Phase III trials, and amisulpride is specifically approved in some European countries for the treatment of negative symptoms. Given the sizable percentage of schizophrenia patients who exhibit negative symptoms and the paucity of therapeutic options in this segment, there is high unmet need and commercial opportunity for an efficacious and safe therapy to treat the negative symptoms of schizophrenia in this underserved segment.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 U.S. and 30 European psychiatrists fielded in January 2021.
Key companies: Janssen, Otsuka Pharmaceutical, AbbVie, Sanofi, Eli Lilly, Lundbeck, Gedeon Richter, Recordati.
Key drugs: Aripiprazole, cariprazine, risperidone,amisulpride, olanzapine, fluoxetine, citalopram.